These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method). Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414 [TBL] [Abstract][Full Text] [Related]
4. 2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests. Zhou Y; Chen L; Jiang T; Fan L; Lei H; Wang Y; Heililahong H; Mi J; Du D; Miao T; Xia R; Wang X; Xiang D; Cai X; Tang X Hematology; 2021 Dec; 26(1):365-370. PubMed ID: 33971806 [TBL] [Abstract][Full Text] [Related]
5. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Chapuy CI; Aguad MD; Nicholson RT; AuBuchon JP; Cohn CS; Delaney M; Fung MK; Unger M; Doshi P; Murphy MF; Dumont LJ; Kaufman RM; Transfusion; 2016 Dec; 56(12):2964-2972. PubMed ID: 27600566 [TBL] [Abstract][Full Text] [Related]
6. Use of an in-house trypsin-based method to resolve the interference of daratumumab. Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116 [TBL] [Abstract][Full Text] [Related]
7. Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients' Plasma. Werle E; Ziebart J; Wasmund E; Eske-Pogodda K Transfus Med Hemother; 2019 Dec; 46(6):423-430. PubMed ID: 31933572 [TBL] [Abstract][Full Text] [Related]
8. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing. Chinoca Ziza KN; Paiva TA; Mota SR; Dezan MR; Schmidt LC; Brunetta DM; Ricci G; Basques FV; Barroso-Duarte F; Rocha V; Mendrone-Junior A; Dinardo CL Transfusion; 2019 May; 59(5):1827-1835. PubMed ID: 30779172 [TBL] [Abstract][Full Text] [Related]
9. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment. Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722 [TBL] [Abstract][Full Text] [Related]
10. Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing. Tremblay T; Branch DR; Loubaki L Transfusion; 2020 Sep; 60(9):2090-2096. PubMed ID: 32632934 [TBL] [Abstract][Full Text] [Related]
11. New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing. Izaguirre EC; Del Mar Luis-Hidalgo M; González LL; Castaño CA Blood Transfus; 2020 Jul; 18(4):290-294. PubMed ID: 32530397 [TBL] [Abstract][Full Text] [Related]
12. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies. Baig NA; Dukek BA; Falbo DK; Wakefield LL; DiGuardo MA; Bobr A; Kreuter JD; Gandhi MJ Vox Sang; 2021 Jan; 116(1):116-122. PubMed ID: 32797679 [TBL] [Abstract][Full Text] [Related]
13. The impact of Daratumumab on transfusion service costs. Cushing MM; DeSimone RA; Goel R; Hsu YS; Parra P; Racine-Brzostek SE; Degtyaryova D; Lo DT; Morrison M; Crowley KM; Rossi A; Vasovic LV Transfusion; 2019 Apr; 59(4):1252-1258. PubMed ID: 30620407 [TBL] [Abstract][Full Text] [Related]
14. The Challenges of Daratumumab in Transfusion Medicine. Dizon MF Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527 [TBL] [Abstract][Full Text] [Related]
15. Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals. Youssef M; Arnesen C; Arledge C; Langley C; Sylvester D; Sikora J; Marques MB; Long Zheng X; Williams LA Transfus Apher Sci; 2019 Apr; 58(2):152-155. PubMed ID: 30639177 [TBL] [Abstract][Full Text] [Related]
16. Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping. Chami B; Okuda M; Moayeri M; Pirenne F; Hidaka Y; Nambiar A; Song Z; Bedel O; Zhang B; Hopke J; Deng G; Zhu C; Macé S; Chiron M; Adrian F; Fukao T; Basile FG; Martin T Transfusion; 2022 Nov; 62(11):2334-2348. PubMed ID: 36239134 [TBL] [Abstract][Full Text] [Related]
17. Transfusion management for patients taking an anti-CD38 monoclonal antibody. Bub CB; Reis IND; Aravechia MG; Santos LD; Bastos EP; Kutner JM; Castilho L Hematol Transfus Cell Ther; 2018; 40(1):25-29. PubMed ID: 29519368 [TBL] [Abstract][Full Text] [Related]
18. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform? Habicht CP; Ridders M; Grueger D; Adolph S; Immenschuh S; Schneeweiss C Transfusion; 2023 Apr; 63(4):808-816. PubMed ID: 36707937 [TBL] [Abstract][Full Text] [Related]
19. A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells. Furumaki H; Takeshita A; Ohto H; Yamada C; Fujihara H; Ishizuka K; Shibata H; Shinba T; Nemoto N; Ino K; Ozawa A; Watanabe H; Kawabata K; Obata Y Vox Sang; 2021 Jul; 116(6):725-734. PubMed ID: 33314130 [TBL] [Abstract][Full Text] [Related]
20. Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol. Pandey P; Setya D; Kaul E; Ranjan S; Singh MK; Shankar A Immunohematology; 2020 Dec; 36(4):157-165. PubMed ID: 33544622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]